Lipe B, Vukas R, Mikhael J
Department of Hematology, University of Rochester, Rochester, NY, USA.
Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.
Blood Cancer J. 2016 Oct 21;6(10):e485. doi: 10.1038/bcj.2016.89.
Multiple myeloma is the second most common type of blood cancer and remains incurable despite advances in therapy. Current therapy for multiple myeloma includes a phased-approach, often consisting of initial induction therapy, consolidation and maintenance therapy. With an ever-growing landscape of treatment options, the approach to optimal therapy has become increasingly complex. Specifically, controversy surrounds the optimal use and duration of maintenance therapy. We conducted a comprehensive literature search to analyze the most current literature and to provide recommendations for maintenance therapy in multiple myeloma.
多发性骨髓瘤是第二常见的血癌类型，尽管治疗方面取得了进展，但仍然无法治愈。目前针对多发性骨髓瘤的治疗采用分阶段方法，通常包括初始诱导治疗、巩固治疗和维持治疗。随着治疗选择的不断增加，实现最佳治疗的方法变得越来越复杂。具体而言，维持治疗的最佳使用方法和持续时间存在争议。我们进行了全面的文献检索，以分析最新的文献，并为多发性骨髓瘤的维持治疗提供建议。
